drugset / Trial / NCT01720537

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

NCT01720537

Phase 1 Completed 133 enrolled Pfizer
RandomizedSingle-groupDouble-blindBasic science

Summary

This study is to evaluate the safety, tolerability and immunogenicity of single, ascending or multiple fixed subcutaneous and intravenous administrations of PF 05335810 to hypercholesterolemic subjects when added on to a daily statin dose.

Timeline

Start
2012-07
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bococizumab Monoclonal antibody Subcutaneous
Subject RALPANCIZUMAB Monoclonal antibody Subcutaneous

Indications